Non-pharmacological treatment of obesity | Pharmacological treatment of obesity |
---|---|
Reduction diet | GLP 1 analogs (liraglutyd, semaglutyd) |
Physical activity | Bupropion and naltrexone |
Bariatric surgery | Orlistat |
Phentermine |
Current research regarding the use of probiotics in body mass reduction | |
---|---|
( |
|
( |
|
( |
|
( |
|
( |
|
( |
|
( |
Species of bacteria FIRMICUTES (examples) | Species of bacteria BACTEROIDETES (examples) |
---|---|
Bacteroides fragilis | |
Bacteroides vulgaris | |
Gut microbiota corresponding with obesity/overweight | Ref | Gut microbiota in normal BMI | Ref |
---|---|---|---|
( |
Supplementation with |
( |
|
Lower level of two species from the family Rikenellaceae, |
( |
Increased levels of |
( |
Reduced level of |
( |
( |
|
Higher levels of |
( |
( |
Source | No. of subjects | Study subject | Duration | Bacteria | Delta weight |
---|---|---|---|---|---|
1. |
32 | Human | 3 months | Akkermansia muciniphila | –2,27 kg +/– 0,92 kg |
2. |
120 | Human | 12 weeks | Lactobacillus curvatus HY7601, Lactobacillus plantarum KY1032 | –0,65 kg +/– 0,23 kg |
3. |
20 | Mice | 20 weeks | Lactobacillus plantarum DSM 15313 | +21,5 g +/– 1,1 g |
4. |
101 | Human | 8 weeks | mixture of Streptococcus thermophilus, Lactobacillus acidophilus, Bifidobacterium infantis and extra-ingredients containing Bifidobacterium breve (CBG-C2), Enterococcus faecalis FK-23 | –0,24 kg +/– 1,5 kg |
5. |
48 | Rats | 6 weeks | Bifidobasteria M13 –4 | +51,72 g |
6. |
60 | Human | 8 weeks | Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum + inulina | –4,01 +/– 4,05 kg |